Trafalgar International (GCAN) Receivables (2020 - 2021)
Trafalgar International (GCAN) posted Receivables of $36750.0 for Q3 2021, little changed on a QoQ basis from $36750.0 in Q2 2021, and up 55.89% year-over-year from $23575.0 in Q3 2020.
Powered by 
Analysis
Trafalgar International (GCAN) Receivables (2020 - 2021) Analysis & Trends
Trafalgar International has reported Receivables for 2 years, with the latest figure at $36750.0 in Q3 2021.
- On a quarterly basis, Receivables rose 55.89% year-over-year to $36750.0 in Q3 2021; TTM through Sep 2021 was $36750.0, a 55.89% increase from a year earlier, with the FY2020 full-year figure at $36750.0, changed N/A from the prior year.
- Receivables was $36750.0 for Q3 2021 at Trafalgar International, roughly flat from $36750.0 in the prior quarter.
- The five-year high for Receivables was $36750.0 in Q4 2020, with the low at $23575.0 in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 19.05 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 13.82 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 12.56 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 9.64 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 12.49 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 10.13 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 1.13 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 310.30 Mn |
| 10 | Trafalgar International | 217,335.05 | 217,335.05 | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2021 | 36,750.00 |
| Jun 30, 2021 | 36,750.00 |
| Mar 31, 2021 | 36,750.00 |
| Dec 31, 2020 | 36,750.00 |
| Sep 30, 2020 | 23,575.00 |
| Jun 30, 2020 | 23,575.00 |